- Home
- IPHA vs PIM Comparison
IPHA vs PIM Comparison
Compare IPHA & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IPHA | PIM |
|---|---|---|
| Founded | 1999 | 1988 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 161.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | IPHA | PIM |
|---|---|---|
| Price | $1.70 | $3.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 26.6K | ★ 57.5K |
| Earning Date | 09-17-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $14,839,695.00 | N/A |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | N/A |
| P/E Ratio | ★ N/A | $63.80 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.63 | $2.90 |
| 52 Week High | $2.63 | $3.28 |
Technical Indicators
Market Signals| Indicator | IPHA | PIM |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 52.11 |
| Support Level | $1.72 | $3.29 |
| Resistance Level | $1.86 | $3.36 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 39.39 | 40.30 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.